A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

NCT03593109 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Suitable patients were not recruited

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

Sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Collaborators

[object Object]